| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
21‑Desacetyldeflazacort‑d₅ targets the same receptor as its non‑deuterated counterpart: the glucocorticoid receptor (GR). Glucocorticoid receptors are intracellular nuclear receptors that, upon binding of the ligand, translocate to the nucleus and regulate the transcription of target genes involved in inflammation, immune response, and metabolism. Activation of GR by 21‑desacetyldeflazacort leads to anti‑inflammatory and immunosuppressive effects. The deuterated version has no direct biological activity; it is used as an analytical internal standard.
|
|---|---|
| ln Vitro |
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Studies involving the human use of drugs labeled with deuterium suggest that these compounds may offer some advantages when compared with their nondeuterated counterparts. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs. Deutetrabenazine is the first deuterated drug to receive Food and Drug Administration approval. This deuterated form of the drug tetrabenazine is indicated for the treatment of chorea associated with Huntington's disease as well as tardive dyskinesia. Ongoing clinical trials suggest that a number of other deuterated compounds are being evaluated for the treatment of human diseases and not merely as research tools.[1]
21‑Desacetyldeflazacort‑d₅ is the deuterium‑labeled form of 21‑desacetyldeflazacort. It is a stable heavy isotope of hydrogen, carbon, and other elements incorporated into drug molecules, largely as tracers for quantitation during the drug development process. The compound can be used as an internal standard for quantitative analysis by NMR, GC‑MS, or LC‑MS. No specific in vitro biological activity data are reported for the deuterated version. |
| ln Vivo |
Deuterated compounds may, in some cases, offer advantages over nondeuterated forms, often through alterations in clearance. Deuteration may also redirect metabolic pathways in directions that reduce toxicities. The approval of additional deuterated compounds may soon follow. Clinicians will need to be familiar with the dosing, efficacy, potential side effects, and unique metabolic profiles of these new entities.
21‑Desacetyldeflazacort‑d₅ has no direct in vivo activity as it is an analytical standard. The non‑deuterated active metabolite, 21‑desacetyldeflazacort, is a potent glucocorticoid receptor agonist with anti‑inflammatory and immunosuppressive effects. Deflazacort (the prodrug) is used clinically to treat Duchenne muscular dystrophy (DMD) and other inflammatory conditions. The deuterated version is not administered in vivo for therapeutic purposes but can be used as an internal standard in pharmacokinetic studies. |
| Enzyme Assay |
21‑Desacetyldeflazacort‑d₅ is not evaluated in enzyme/receptor binding assays. As an analytical internal standard, its properties are characterized by chemical methods: HPLC to confirm purity (typically >99.3%), mass spectrometry to confirm isotopic enrichment (≥98% deuterium), and NMR to confirm structure. The compound is used to spike into biological samples for the quantification of 21‑desacetyldeflazacort. No bioactivity assays are performed.
|
| Cell Assay |
No cellular experiments are performed on 21‑desacetyldeflazacort‑d₅. For analytical studies, cells are cultured and treated with deflazacort, which is metabolized to 21‑desacetyldeflazacort. A known amount of 21‑desacetyldeflazacort‑d₅ is added to the cell lysate or culture supernatant as an internal standard. 21‑Desacetyldeflazacort is extracted (e.g., by protein precipitation with acetonitrile or methanol) and quantified by LC‑MS/MS using multiple reaction monitoring (MRM). The ratio of the peak area of unlabeled 21‑desacetyldeflazacort to deuterated internal standard is used to calculate the concentration.
|
| Animal Protocol |
No animal experiments are performed directly on 21‑desacetyldeflazacort‑d₅. For pharmacokinetic studies, deflazacort is administered to animals (e.g., rats or dogs) by oral gavage. Blood samples are collected at various time points. A known amount of 21‑desacetyldeflazacort‑d₅ is added to each plasma sample as an internal standard. 21‑Desacetyldeflazacort is extracted, and the concentration in each sample is quantified by LC‑MS/MS. The pharmacokinetic parameters (Cmax, Tmax, AUC, t½) for the active metabolite are then calculated.
|
| ADME/Pharmacokinetics |
21‑Desacetyldeflazacort‑d₅ (C23H24D₅NO₅, MW = 404.51, purity >99.3%, CAS 13649-57-5) is a solid powder. For storage, the powder should be kept at -20 degC for up to 3 years, sealed and protected from light. For analytical use, stock solutions in methanol, acetonitrile, or DMSO (1‑10 mg/mL) can be prepared and stored at -20 degC. The compound is stable under these conditions for extended periods. No PK data are generated for the deuterated compound itself.
|
| Toxicity/Toxicokinetics |
No specific toxicity data for 21‑desacetyldeflazacort‑d₅ are reported. As a research‑grade analytical standard, it is not intended for human or veterinary use. Standard laboratory safety precautions for handling chemicals should be followed. Glucocorticoids as a class can cause significant side effects with chronic use, including immunosuppression, weight gain, hyperglycemia, osteoporosis, and adrenal suppression. However, the deuterated version is used at trace amounts and is not therapeutically active.
|
| References | |
| Additional Infomation |
21‑Desacetyldeflazacort‑d₅ is a stable isotope‑labeled internal standard for the quantification of the active metabolite of deflazacort. Deflazacort is a glucocorticoid prodrug used to treat Duchenne muscular dystrophy (DMD), rheumatoid arthritis, and other inflammatory conditions. After oral administration, deflazacort is rapidly converted to its active metabolite 21‑desacetyldeflazacort, which binds to the glucocorticoid receptor with high affinity. The deuterated version (d₅) has five deuterium atoms, providing a mass shift of +5 Da for LC‑MS/MS analysis. This product is for research use only and is not intended for human consumption.
|
| Molecular Formula |
C23H24D5NO5
|
|---|---|
| Molecular Weight |
404.51
|
| Appearance |
Solid powder
|
| Synonyms |
21-desDFZ-d5
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMF : ≥ 30 mg/mL (74.16 mM) DMSO : ≥ 30 mg/mL (74.16 mM)
Ethanol : ≥ 1 mg/mL (2.47 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4721 mL | 12.3606 mL | 24.7213 mL | |
| 5 mM | 0.4944 mL | 2.4721 mL | 4.9443 mL | |
| 10 mM | 0.2472 mL | 1.2361 mL | 2.4721 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
